Josh Schimmer
Stock Analyst at Cantor Fitzgerald
(4.40)
# 379
Out of 5,138 analysts
147
Total ratings
54.55%
Success rate
17.77%
Average return
Main Sectors:
Stocks Rated by Josh Schimmer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MIRM Mirum Pharmaceuticals | Maintains: Overweight | $95 → $130 | $92.32 | +40.81% | 7 | Dec 8, 2025 | |
| JANX Janux Therapeutics | Maintains: Overweight | $200 → $150 | $13.72 | +993.29% | 7 | Dec 2, 2025 | |
| DMAC DiaMedica Therapeutics | Initiates: Overweight | $25 | $8.54 | +192.74% | 1 | Nov 14, 2025 | |
| PVLA Palvella Therapeutics | Maintains: Overweight | $120 → $200 | $103.72 | +92.83% | 1 | Nov 6, 2025 | |
| CABA Cabaletta Bio | Maintains: Overweight | $15 → $30 | $2.08 | +1,342.31% | 3 | Oct 31, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $100 → $110 | $76.26 | +44.24% | 13 | Oct 30, 2025 | |
| NUVL Nuvalent | Initiates: Overweight | $135 | $106.16 | +27.17% | 1 | Oct 15, 2025 | |
| IVVD Invivyd | Initiates: Overweight | $10 | $2.44 | +309.84% | 1 | Oct 6, 2025 | |
| RNA Avidity Biosciences | Maintains: Outperform | $70 → $65 | $72.60 | -10.47% | 6 | Sep 22, 2025 | |
| CGON CG Oncology | Reiterates: Overweight | $75 | $53.07 | +41.32% | 5 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $18.78 | - | 3 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $27.38 | -8.69% | 4 | Sep 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $8 | $3.71 | +115.63% | 7 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $25 | $10.76 | +132.34% | 1 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $11 → $6 | $7.31 | -17.92% | 2 | Jun 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $260 → $280 | $215.04 | +30.21% | 4 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $15.35 | +225.73% | 2 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $20 | $4.46 | +348.43% | 2 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $215 | $282.01 | -23.76% | 5 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $5 | $2.40 | +108.33% | 4 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $4.69 | - | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $30 | $11.09 | +170.51% | 4 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $7.61 | - | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.82 | - | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $90 | $56.43 | +59.49% | 6 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.52 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $159.27 | - | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $66.25 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $7.61 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $6.16 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $68.32 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 | $0.68 | +2,118.93% | 3 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $40.74 | +59.55% | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $43 → $5 | $13.86 | -63.92% | 2 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $11 | $9.56 | +15.06% | 2 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $140 → $130 | $133.35 | -2.51% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $760 | $741.92 | +2.44% | 2 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $23.63 | -36.52% | 1 | Mar 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $55 | $10.66 | +415.95% | 1 | Feb 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $1.77 | +1,594.92% | 1 | Dec 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $1.25 | - | 4 | Dec 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $13.76 | - | 3 | Feb 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $222 → $250 | $495.89 | -49.59% | 4 | Nov 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $105.24 | - | 2 | Jun 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $77.21 | - | 2 | May 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $3.82 | - | 2 | Mar 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $21.98 | +0.09% | 1 | Nov 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $20.11 | - | 2 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $55.07 | - | 1 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $95 | $216.75 | -56.17% | 1 | Aug 17, 2017 |
Mirum Pharmaceuticals
Dec 8, 2025
Maintains: Overweight
Price Target: $95 → $130
Current: $92.32
Upside: +40.81%
Janux Therapeutics
Dec 2, 2025
Maintains: Overweight
Price Target: $200 → $150
Current: $13.72
Upside: +993.29%
DiaMedica Therapeutics
Nov 14, 2025
Initiates: Overweight
Price Target: $25
Current: $8.54
Upside: +192.74%
Palvella Therapeutics
Nov 6, 2025
Maintains: Overweight
Price Target: $120 → $200
Current: $103.72
Upside: +92.83%
Cabaletta Bio
Oct 31, 2025
Maintains: Overweight
Price Target: $15 → $30
Current: $2.08
Upside: +1,342.31%
BridgeBio Pharma
Oct 30, 2025
Maintains: Overweight
Price Target: $100 → $110
Current: $76.26
Upside: +44.24%
Nuvalent
Oct 15, 2025
Initiates: Overweight
Price Target: $135
Current: $106.16
Upside: +27.17%
Invivyd
Oct 6, 2025
Initiates: Overweight
Price Target: $10
Current: $2.44
Upside: +309.84%
Avidity Biosciences
Sep 22, 2025
Maintains: Outperform
Price Target: $70 → $65
Current: $72.60
Upside: -10.47%
CG Oncology
Sep 8, 2025
Reiterates: Overweight
Price Target: $75
Current: $53.07
Upside: +41.32%
Sep 8, 2025
Reiterates: Overweight
Price Target: n/a
Current: $18.78
Upside: -
Sep 5, 2025
Reiterates: Overweight
Price Target: $25
Current: $27.38
Upside: -8.69%
Aug 8, 2025
Maintains: Overweight
Price Target: $10 → $8
Current: $3.71
Upside: +115.63%
Jul 1, 2025
Initiates: Overweight
Price Target: $25
Current: $10.76
Upside: +132.34%
Jun 23, 2025
Downgrades: In-Line
Price Target: $11 → $6
Current: $7.31
Upside: -17.92%
May 2, 2025
Maintains: Outperform
Price Target: $260 → $280
Current: $215.04
Upside: +30.21%
Apr 1, 2025
Reiterates: Overweight
Price Target: $50
Current: $15.35
Upside: +225.73%
Mar 25, 2025
Maintains: Overweight
Price Target: $23 → $20
Current: $4.46
Upside: +348.43%
Feb 20, 2025
Reiterates: Overweight
Price Target: $215
Current: $282.01
Upside: -23.76%
Dec 20, 2024
Downgrades: In-Line
Price Target: $5
Current: $2.40
Upside: +108.33%
Dec 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.69
Upside: -
Oct 8, 2024
Reiterates: Overweight
Price Target: $30
Current: $11.09
Upside: +170.51%
Sep 23, 2024
Downgrades: Neutral
Price Target: n/a
Current: $7.61
Upside: -
Sep 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.82
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $90
Current: $56.43
Upside: +59.49%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.52
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $159.27
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $66.25
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.61
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $6.16
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $68.32
Upside: -
Aug 26, 2024
Maintains: Outperform
Price Target: $15
Current: $0.68
Upside: +2,118.93%
Aug 9, 2024
Reiterates: Overweight
Price Target: $65
Current: $40.74
Upside: +59.55%
Nov 10, 2023
Downgrades: In-Line
Price Target: $43 → $5
Current: $13.86
Upside: -63.92%
Jun 6, 2023
Maintains: Outperform
Price Target: $20 → $11
Current: $9.56
Upside: +15.06%
Nov 14, 2022
Downgrades: In-Line
Price Target: $140 → $130
Current: $133.35
Upside: -2.51%
Oct 17, 2022
Downgrades: In-Line
Price Target: $760
Current: $741.92
Upside: +2.44%
Mar 15, 2022
Initiates: Outperform
Price Target: $15
Current: $23.63
Upside: -36.52%
Feb 2, 2021
Initiates: Outperform
Price Target: $55
Current: $10.66
Upside: +415.95%
Dec 29, 2020
Initiates: Outperform
Price Target: $30
Current: $1.77
Upside: +1,594.92%
Dec 9, 2019
Downgrades: In-Line
Price Target: n/a
Current: $1.25
Upside: -
Feb 25, 2019
Upgrades: Outperform
Price Target: n/a
Current: $13.76
Upside: -
Nov 16, 2018
Upgrades: Outperform
Price Target: $222 → $250
Current: $495.89
Upside: -49.59%
Jun 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $105.24
Upside: -
May 8, 2018
Downgrades: In-Line
Price Target: n/a
Current: $77.21
Upside: -
Mar 12, 2018
Downgrades: In-Line
Price Target: n/a
Current: $3.82
Upside: -
Nov 7, 2017
Initiates: Outperform
Price Target: $22
Current: $21.98
Upside: +0.09%
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $20.11
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $55.07
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: $95
Current: $216.75
Upside: -56.17%